<code id='C632A6F4AA'></code><style id='C632A6F4AA'></style>
    • <acronym id='C632A6F4AA'></acronym>
      <center id='C632A6F4AA'><center id='C632A6F4AA'><tfoot id='C632A6F4AA'></tfoot></center><abbr id='C632A6F4AA'><dir id='C632A6F4AA'><tfoot id='C632A6F4AA'></tfoot><noframes id='C632A6F4AA'>

    • <optgroup id='C632A6F4AA'><strike id='C632A6F4AA'><sup id='C632A6F4AA'></sup></strike><code id='C632A6F4AA'></code></optgroup>
        1. <b id='C632A6F4AA'><label id='C632A6F4AA'><select id='C632A6F4AA'><dt id='C632A6F4AA'><span id='C632A6F4AA'></span></dt></select></label></b><u id='C632A6F4AA'></u>
          <i id='C632A6F4AA'><strike id='C632A6F4AA'><tt id='C632A6F4AA'><pre id='C632A6F4AA'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:12666
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

          John-ArneRøttingenistheheadoftheWellcomeTrust,oneoftheworld’stopprivatefundersofbiomedicalresearch.I

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Biden tests positive for Covid

          PresidentJoeBidenremoveshisfacemaskashearrivestospeakduringameetingwithCEOsintheWhiteHousecomplexThu